Update on the Medical Management of Crohn’s Disease

Parakkal Deepak, David H. Bruining

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The medical management of Crohn’s disease is a rapidly evolving field with expanding therapeutic drug options and treatment strategies. In addition to corticosteroids, immunomodulators, and anti-tumor necrosis (anti-TNF) agents, a new anti-adhesion medication (vedolizumab) has been approved. Individualized patient-based dosing of immunomodulators and biologic agents is now possible with therapeutic drug monitoring (TDM). There is a changing paradigm in treatment goals to achieve deeper remission identified by composite clinical and endoscopic endpoints. More aggressive treatment strategies in the postoperative setting have been proposed due to emerging data on medication efficacy in this setting. Management algorithms that stratify CD patients into risk groups to balance treatment benefit against adverse events and costs are being developed to translate research into clinical practice. This review provides an update on these new developments for practicing gastroenterologists.

Original languageEnglish (US)
Article number41
JournalCurrent Gastroenterology Reports
Volume17
Issue number11
DOIs
StatePublished - Nov 22 2015

Fingerprint

Crohn Disease
Immunologic Factors
Therapeutics
Drug Monitoring
Biological Factors
Adrenal Cortex Hormones
Necrosis
Costs and Cost Analysis
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antibodies
  • Crohn’s disease management
  • Drug monitoring
  • Humanized/therapeutic use
  • Monoclonal
  • Tumor necrosis factor-alpha/antagonists and inhibitors

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Update on the Medical Management of Crohn’s Disease. / Deepak, Parakkal; Bruining, David H.

In: Current Gastroenterology Reports, Vol. 17, No. 11, 41, 22.11.2015.

Research output: Contribution to journalArticle

Deepak, Parakkal ; Bruining, David H. / Update on the Medical Management of Crohn’s Disease. In: Current Gastroenterology Reports. 2015 ; Vol. 17, No. 11.
@article{f5fc307886ec494c995dd8958cff3421,
title = "Update on the Medical Management of Crohn’s Disease",
abstract = "The medical management of Crohn’s disease is a rapidly evolving field with expanding therapeutic drug options and treatment strategies. In addition to corticosteroids, immunomodulators, and anti-tumor necrosis (anti-TNF) agents, a new anti-adhesion medication (vedolizumab) has been approved. Individualized patient-based dosing of immunomodulators and biologic agents is now possible with therapeutic drug monitoring (TDM). There is a changing paradigm in treatment goals to achieve deeper remission identified by composite clinical and endoscopic endpoints. More aggressive treatment strategies in the postoperative setting have been proposed due to emerging data on medication efficacy in this setting. Management algorithms that stratify CD patients into risk groups to balance treatment benefit against adverse events and costs are being developed to translate research into clinical practice. This review provides an update on these new developments for practicing gastroenterologists.",
keywords = "Antibodies, Crohn’s disease management, Drug monitoring, Humanized/therapeutic use, Monoclonal, Tumor necrosis factor-alpha/antagonists and inhibitors",
author = "Parakkal Deepak and Bruining, {David H.}",
year = "2015",
month = "11",
day = "22",
doi = "10.1007/s11894-015-0465-x",
language = "English (US)",
volume = "17",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - Update on the Medical Management of Crohn’s Disease

AU - Deepak, Parakkal

AU - Bruining, David H.

PY - 2015/11/22

Y1 - 2015/11/22

N2 - The medical management of Crohn’s disease is a rapidly evolving field with expanding therapeutic drug options and treatment strategies. In addition to corticosteroids, immunomodulators, and anti-tumor necrosis (anti-TNF) agents, a new anti-adhesion medication (vedolizumab) has been approved. Individualized patient-based dosing of immunomodulators and biologic agents is now possible with therapeutic drug monitoring (TDM). There is a changing paradigm in treatment goals to achieve deeper remission identified by composite clinical and endoscopic endpoints. More aggressive treatment strategies in the postoperative setting have been proposed due to emerging data on medication efficacy in this setting. Management algorithms that stratify CD patients into risk groups to balance treatment benefit against adverse events and costs are being developed to translate research into clinical practice. This review provides an update on these new developments for practicing gastroenterologists.

AB - The medical management of Crohn’s disease is a rapidly evolving field with expanding therapeutic drug options and treatment strategies. In addition to corticosteroids, immunomodulators, and anti-tumor necrosis (anti-TNF) agents, a new anti-adhesion medication (vedolizumab) has been approved. Individualized patient-based dosing of immunomodulators and biologic agents is now possible with therapeutic drug monitoring (TDM). There is a changing paradigm in treatment goals to achieve deeper remission identified by composite clinical and endoscopic endpoints. More aggressive treatment strategies in the postoperative setting have been proposed due to emerging data on medication efficacy in this setting. Management algorithms that stratify CD patients into risk groups to balance treatment benefit against adverse events and costs are being developed to translate research into clinical practice. This review provides an update on these new developments for practicing gastroenterologists.

KW - Antibodies

KW - Crohn’s disease management

KW - Drug monitoring

KW - Humanized/therapeutic use

KW - Monoclonal

KW - Tumor necrosis factor-alpha/antagonists and inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84941887963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941887963&partnerID=8YFLogxK

U2 - 10.1007/s11894-015-0465-x

DO - 10.1007/s11894-015-0465-x

M3 - Article

VL - 17

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 11

M1 - 41

ER -